CAV Regimen for R/R Ph- B-ALL: a Single-arm, Multicenter Study
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of cladribine, venetoclax combined
with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia
Chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Affiliated Hospital of Nantong University First Affiliated Hospital Bengbu Medical College Jining Medical University Northern Jiangsu Province People's Hospital Suzhou Hospital of Traditional Chinese Medicine The Second People's Hospital of Huai'an